For Long COVID, studies are trying extremely small microdoses of GLP-1s. You can purchase a vial of Wegovy direct from Novo Nordisk for $499 and it will last for months when microdosing. Here is some info on a study at Scripps:

- A new clinical trial launched by Scripps Research, known as the Long COVID Treatment Trial (LoCITT), is investigating the use of tirzepatide, a GLP-1 receptor agonist, for treating long COVID symptoms through a digital, remote platform.
This trial will assess whether microdosing tirzepatide—marketed as Mounjaro for diabetes and Zepbound for weight loss—can reduce symptoms such as fatigue, brain fog, and joint pain over a 12-month period.
The study aims to enroll 1,000 participants across the U.S. who have medically documented long COVID, with half receiving the drug and half a placebo to ensure scientific rigor.

The rationale for using GLP-1 drugs stems from their anti-inflammatory properties, which may address underlying inflammation associated with long COVID.
While there are currently no FDA-approved treatments for long COVID, anecdotal reports and early physician observations have spurred interest in repurposing GLP-1 agonists.
Some patients with ME/CFS, fibromyalgia, and long COVID have reported significant improvements in cognitive function and fatigue after using low doses of these medications, although responses vary and some individuals experience adverse effects like worsened brain fog or sleep disruption.

Due to the sensitivity of patients with chronic conditions, experts recommend starting at much lower doses than those approved for diabetes or obesity, a practice referred to as microdosing.
In the U.S., this is typically done using vials of tirzepatide from which precise microdoses can be drawn with a syringe, as pre-filled pens do not allow dose adjustment.
The Scripps trial will titrate doses gradually, beginning low and increasing only if well-tolerated, to find each participant’s optimal dose without triggering side effects.